Ocular tuberculosis

Summary

Ocular tuberculosis (MONDO:0006876) is a disease. A subtype of extrapulmonary tuberculosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ocular tuberculosis
Mondo ID	MONDO:0006876
EFO	EFO:1001070
MeSH	D014392
DOID	DOID:0070344
SNOMED CT	49107007
UMLS	C0041322
MedGen	52887
GARD	0024495
Anatomy (UBERON)	UBERON:0000970
Is cancer (heuristic)	no

Disease family

This is a subtype of extrapulmonary tuberculosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › tuberculosis › extrapulmonary tuberculosis › ocular tuberculosis

Related subtypes (12): abdominal tuberculosis, cardiac tuberculosis, central nervous system tuberculosis, gastrointestinal tuberculosis, laryngeal tuberculosis, lymph node tuberculosis, miliary tuberculosis, pericardial tuberculosis, pleural tuberculosis, skeletal tuberculosis, urogenital tuberculosis, cutaneous tuberculosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.